Overview

A Study of MG1111 in Healthy Children

Status:
Completed
Trial end date:
2019-07-31
Target enrollment:
Participant gender:
Summary
To assess the safety of MG1111 and to evaluate immunological non-inferiority of MG1111 versus comparator
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Green Cross Corporation
Treatments:
Vaccines